Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda
Astex Pharmaceuticals, Inc. 04.12.2012 12:00 --------------------------------------------------------------------------- DUBLIN, Calif., 2012-12-04 12:00 CET (GLOBE NEWSWIRE) -- DUBLIN, Calif., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the agenda for its Analyst and Investor Day webcast, to take place from 10 am to 12:15 pm GMT on Friday, December 14th in London, UK. Investors and interested parties may access the webcast in the Investor Events section of the Company's website, www.astx.com. A webcast replay will be available for 90 days following the live event. 10:00 (5 Welcome and Introductions Timothy L. Enns min.) SVP, Corporate Communications and Marketing 10:05 (10 Corporate Overview James S.J. Manuso, PhD, MBA min.) Chairman and Chief Executive Officer 10:15 (20 Clinical Update Mohammad Azab, MD, M Sc, MBA min.) Chief Medical Officer 10:35 (25 AT13387 & Prostate Cancer Johann de Bono, MD, PhD min.) Royal Marsden Hospital Institute of Cancer Research (ICR) 11:00 (25 SGI-110 & Ovarian Cancer Robert Brown, PhD min.) Imperial College London Institute of Cancer Research (ICR) 11:25 (20 Research & Discovery Harren Jhoti, PhD min.) President and Director 11:45 (15 Partnering & Corporate Martin Buckland, DPhil, MBA min.) Development Chief Business Officer 12:00 (10 Financial Overview Michael Molkentin, CPA min.) Chief Financial Officer and Corporate Secretary 12:10 (5 Closing Remarks James S.J. Manuso, PhD, MBA min.) Chairman and Chief Executive Officer The times listed above are approximate and are subject to change. About Astex Pharmaceuticals Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN(R) (decitabine) for Injection and receives significant royalties on global sales. For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com. The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273 Timothy L. Enns Astex Pharmaceuticals, Inc. Senior Vice President Corporate Communications & Marketing Tel: +1 (925) 560-2810 E-mail: tim.enns@astx.com Susanna Chau Astex Pharmaceuticals, Inc. Manager Investor Relations Tel: +1 (925) 560-2845 E-mail: susanna.chau@astx.com Alan Roemer The Trout Group Managing Director Tel: +1 (646) 378-2945 E-mail: aroemer@troutgroup.com Kari Watson MacDougall Biomedical Communications Senior Vice President Tel: +1 (781) 235-3060 E-mail: kwatson@macbiocom.com News Source: NASDAQ OMX 04.12.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Astex Pharmaceuticals, Inc. United States Phone: Fax: E-mail: Internet: ISIN: US04624B1035 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found